Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein L16 (MRPL16) is a protein encoded by nuclear DNA that is integrated into the large (39S) subunit of the mammalian mitochondrial ribosome. It plays a crucial role as a structural component in the assembly and stabilization of the mitochondrial ribosome required for protein translation within the mitochondrion. Unlike cytoplasmic ribosomal proteins, mitochondrial ribosomal proteins—including MRPL16—show significant sequence divergence among species, making their identification by homology more challenging. MRPL16 has been implicated in rare inherited mitochondrial disorders, such as combined oxidative phosphorylation deficiency, due to its essential role in mitochondrial gene expression and energy production. Its function is widely conserved in eukaryotes, and it is primarily involved in mitochondrial protein synthesis, but it is not considered a direct or actionable therapeutic target in pharmacology.
Not applicable; no existing drugs target this protein directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L16 (MRPL16).